Corbus MACD and KDJ Death Crosses Triggered on 15min Chart
ByAinvest
Thursday, Oct 2, 2025 12:34 pm ET1min read
CRBP--
Analysts have also shown caution towards Corbus' stock. Oppenheimer lowered its price target to $53.00 from $60.00, while maintaining an Outperform rating. This adjustment comes ahead of Corbus' presentation at the European Society for Medical Oncology (ESMO) conference, where the company will discuss results from approximately 100 additional patients treated with its Nectin-4 targeting ADC, CRB-701 [1].
Corbus is set to present data on CRB-701 at the ESMO conference, with a key opinion leader event scheduled for October 19, 2025, focusing on head and neck squamous cell carcinoma (HNSCC) and cervical cancer patients. The presentation is expected to strengthen both safety and efficacy datasets for CRB-701 [1].
Additionally, Corbus received an FDA Fast Track Designation for CRB-701, which is intended for treating recurrent or metastatic head and neck squamous cell carcinoma. Mizuho reiterated its Outperform rating for Corbus, maintaining a price target of $32.00. Corbus will also present updated clinical data from its Phase 1/2 study of CRB-701 at the ESMO Congress in October 2025, covering results from trials involving patients with urothelial and non-urothelial solid tumors [1].
Corbus has initiated the multiple ascending dose portion of its Phase 1 trial for CRB-913, aimed at treating obesity. This phase follows the single ascending dose portion completed earlier in the year, with no treatment-related neuropsychiatric events reported [1].
Corbus's 15-minute chart has triggered a MACD Death Cross and KDJ Death Cross as of 10/02/2025 at 12:30. This indicates that the stock price is susceptible to further declines and the momentum is shifting towards a downward trajectory.
Corbus Pharmaceuticals (NASDAQ: CRBP) stock experienced a significant technical setback as of October 2, 2025, at 12:30, with the 15-minute chart indicating a MACD Death Cross and KDJ Death Cross. This development suggests a potential downward trend in the stock price, signaling a shift in momentum [1].Analysts have also shown caution towards Corbus' stock. Oppenheimer lowered its price target to $53.00 from $60.00, while maintaining an Outperform rating. This adjustment comes ahead of Corbus' presentation at the European Society for Medical Oncology (ESMO) conference, where the company will discuss results from approximately 100 additional patients treated with its Nectin-4 targeting ADC, CRB-701 [1].
Corbus is set to present data on CRB-701 at the ESMO conference, with a key opinion leader event scheduled for October 19, 2025, focusing on head and neck squamous cell carcinoma (HNSCC) and cervical cancer patients. The presentation is expected to strengthen both safety and efficacy datasets for CRB-701 [1].
Additionally, Corbus received an FDA Fast Track Designation for CRB-701, which is intended for treating recurrent or metastatic head and neck squamous cell carcinoma. Mizuho reiterated its Outperform rating for Corbus, maintaining a price target of $32.00. Corbus will also present updated clinical data from its Phase 1/2 study of CRB-701 at the ESMO Congress in October 2025, covering results from trials involving patients with urothelial and non-urothelial solid tumors [1].
Corbus has initiated the multiple ascending dose portion of its Phase 1 trial for CRB-913, aimed at treating obesity. This phase follows the single ascending dose portion completed earlier in the year, with no treatment-related neuropsychiatric events reported [1].
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet